Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program

被引：0

作者：

Warren, Richard B. ^{[1
]}

Armstrong, April W. ^{[2
]}

Imafuku, Shinichi ^{[3
]}

Paul, Carle ^{[4
,5
]}

Kircik, Leon ^{[6
]}

Colston, Elizabeth ^{[7
]}

Scharnitz, Thomas ^{[7
]}

Wang, Tao ^{[7
]}

Banerjee, Subhashis ^{[7
]}

Strober, Bruce ^{[8
,9
]}

机构：

[1] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Salford, Lancs, England

[2] Univ Southern Calif, Los Angeles, CA USA

[3] Fukuoka Univ Hosp, Fukuoka, Japan

[4] Univ Toulouse, Toulouse, France

[5] CHU, Toulouse, France

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Bristol Myers Squibb, New York, NY USA

[8] Yale Univ, Sch Med, New Haven, CT USA

[9] Cent Connecticut Dermatol Res, Cromwell, CT USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

43879

引用

页码：AB147 / AB147

页数：1

共 50 条

[31] Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
Gottlieb, Alice B.
Armstrong, April W.
Merola, Joseph
Napoli, Andrew
Nowak, Miroslawa
Banerjee, Subhashis
Lehman, Thomas
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2782 - 2785
[32] EFFICACY OF THE ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA)
Gottlieb, Alice B.
Armstrong, April W.
Merola, Joseph F.
Napoli, Andrew
Nowak, Miroslawa
Banerjee, Subhashis
Lehman, Thomas
Mease, Philip J.
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[33] Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
Merola, Joseph
Mease, Philip J.
Armstrong, April W.
Strand, Vibeke
Lehman, Thomas
Choi, Jiyoon
Becker, Brandon
Zhong, Yichen
Colombo, Matthew J.
Thaci, Diamant
Bili, Androniki
Gottlieb, Alice B.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4462 - 4465
[34] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials
Kearney, Niamh
Pink, Andrew
Hoyt, Kim
Kisa, Renata M.
Banerjee, Subhashis
Rogers, Alexandra
Mullan, Jill
Warren, Richard B.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I60 - I61
[35] Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies
Armstrong, April W.
Strober, Bruce
Gordon, Kenneth
Zhuo, Joe
Becker, Brandon
Kisa, Renata
Throup, John
Kim, Jonghyeon
Dirschka, Thomas
Papp, Kim Alexander
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 24 - 25
[36] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and PSO-2 trials
Foley, Peter
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 66 - 66
[37] Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial
Zhang, Jianzhong
Ding, Yangfeng
Wang, Ping
Li, Linfeng
Pan, Weili
Lu, Yan
Cheng, Hao
Jiang, Xian
Ho, Ji-Chen
Guo, Shuping
Liu, Leona
Chatterjee, Arkendu
Kisa, Renata M.
Banerjee, Subhashis
BRITISH JOURNAL OF DERMATOLOGY, 2025, 192 (03) : 402 - 409
[38] Deucravacitinib in moderate to severe plaque psoriasis: Correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
Rubel, Diana
Armstrong, April W.
Papp, Kim
Zhuo, Joe
Becker, Brandon
Zhong, Yichen
Beaumont, Jennifer
DeRosa, Michael
Kisa, Renata M.
Banerjee, Subhashis
Strober, Bruce
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 71 - 72
[39] Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, vs. placebo and apremilast in moderate-to-severe plaque psoriasis: achievement of absolute Psoriasis Area and Severity Index thresholds in two phase III trials
Warren, Richard B.
Lebwohl, Mark
Gooderham, Melinda
Thaci, Diamant
Foley, Peter
Gottlieb, Alice B.
Banerjee, Subhashis
Hippeli, Lauren
Kisa, Renata M.
Griffiths, Christopher E. M.
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[40] Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Psoriasis: Absolute PASI Outcomes in a Phase 3 Trial
Okubo, Yukari
Imafuku, Shinichi
Tada, Yayoi
Ohtsuki, Mamitaro
Shao, Yanqiu
Colston, Elizabeth
Napoli, Andrew
Hippeli, Lauren
Banerjee, Subhashis
Morita, Akimichi
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147

← 1 2 3 4 5 →